The Bracco Group is an Italian multinational active in the healthcare sector with more than 3,300 employees worldwide, which operates in a variety of business areas. Diagnostic imaging, with products for X-ray imaging, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and nuclear medicine. Contrast-agent injection systems and advanced medical devices. Prescription and over-the-counter pharmaceuticals, supplements, medical and cosmetic devices developed and distributed in Italy. Healthcare, prevention, diagnosis and rehabilitation services through the CDI - Centro Diagnostico Italiano. Bracco has consolidated revenues of more than 1.1 billion euro, of which 75% from international sales. The Group is present in 100 countries and invests approximately 10% of its core diagnostic imaging revenues in research and innovation. In Italy Bracco is also a brand associated with a number of historic pharmaceutical products such as Cebion, Xamamina, Euclorina, the Alfa eye-drops line and the Friliver range of sport supplements. The Group Chairman and Chief Executive Officer is Diana Bracco. A chemistry graduate from the University of Pavia, Diana Bracco is also Chairman of Expo 2015 Spa, General Section Commissioner for the Italy Pavilion at Expo and Confindustria Vice President for Research & Innovation. Decorated as a Cavaliere del Lavoro, she was President of Assolombarda and, before that, Chairman of Federchimica. In February 2001 she received an Honorary Doctor of Pharmacy degree from University of Pavia. On January 12, 2015, Diana Bracco was "prosecuted on charges of tax evasion and embezzlement, crimes allegedly committed as chairman of the board of the pharmaceutical group Bracco Spa." In October 2016, she was given a two year suspended sentence for tax fraud and embezzlement.
